Therakos

Develops and markets an extracorporeal photopheresis system (ECP), or immune modulation therapy, for cutaneous T-cell lymphoma (CTCL). Global leader in the advancement of this science

Latest News

• September 28, 2015 – The Gores Group Completes Sale of Therakos
• August 10, 2015 – The Gores Group Enters Into Definitive Agreement to Sell Therakos to Mallinckrodt Pharmaceuticals
• January 2, 2013 – The Gores Group Completes the Acquisition of Therakos, Inc. From Ortho-Clinical Diagnostics, Inc.